Compare $CNSY vs $GTBP | Chartloom

Compare

$CNSY vs $GTBP

Plus Therapeutics Inc · GT Biopharma Inc

CNSY

Plus Therapeutics Inc

GTBP

GT Biopharma Inc

Compare $CNSY vs $GTBP

Comparing Plus Therapeutics Inc and GT Biopharma Inc

CNSYPlus Therapeutics Inc

GTBPGT Biopharma Inc

CNSYPlus Therapeutics Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.12x

Rev growth (TTM)

—

YTD performance

-45.2%

52W performance

-45.2%

FCF yield

-267.6%

GTBPGT Biopharma Inc

Market cap

$296M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-75.3%

FCF yield

-4.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CNSY

GTBP

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

GTBP

GT Biopharma Inc

Market Cap

CNSY$13M

GTBP$296M

Enterprise Value

CNSY$11M

GTBP$291M

Price

CNSY$1.93

GTBP$6.68

P/E Ratio

CNSYN/A

GTBPN/A

P/S Ratio

CNSY3.16x

GTBP174.71x

EV/Sales

CNSY2.60x

GTBP95.98x

EV/EBITDA

CNSY0.00x

GTBP0.00x

P/B Ratio

CNSY2.22x

GTBP3.08x

P/FCF Ratio

CNSYN/A

GTBPN/A

EV/FCF

CNSY-0.31x

GTBP-20.19x

PEG Ratio

CNSYN/A

GTBPN/A

Forward P/E (NTM)

CNSYN/A

GTBPN/A

Forward P/S (NTM)

CNSY1.12x

GTBPN/A

Revenue (TTM)

CNSY$4M

GTBP$0

Revenue Growth (YoY)

CNSYN/A

GTBPN/A

Forward Rev Growth

CNSY216.6%

GTBP216.5%

Gross Margin (TTM)

CNSY0.0%

GTBP36.5%

Operating Margin (TTM)

CNSY0.0%

GTBP0.0%

EBITDA Margin (TTM)

CNSY-612.0%

GTBP0.0%

Net Margin (TTM)

CNSY-620.7%

GTBP0.0%

FCF Margin (TTM)

CNSY-845.3%

GTBPN/A

Net Income (TTM)

CNSY$-26M

GTBP$-33M

FCF (TTM)

CNSY$-36M

GTBP$-14M

EPS (TTM)

CNSY-$3.78

GTBP-$21.10

ROE (TTM)

CNSY-39417.0%

GTBP-44308.0%

ROA (TTM)

CNSY-15136.0%

GTBP-31311.0%

ROIC (TTM)

CNSY-37414.0%

GTBP-44308.0%

Cash

CNSY$2M

GTBP$5M

Debt

CNSY$0

GTBP$0

Net Cash/Debt

CNSY$2M

GTBP$5M

Current Ratio (TTM)

CNSY1.37x

GTBP2.61x

Quick Ratio (TTM)

CNSY1.26x

GTBP2.51x

Debt/Equity (TTM)

CNSY0.19x

GTBP0.00x

Debt/Assets (TTM)

CNSY0.0%

GTBP0.0%

Interest Coverage (TTM)

CNSYN/A

GTBPN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

GTBP0.00x

Beta

CNSY2.21

GTBP0.81

52W Performance

CNSY-45.2%

GTBP-75.3%

YTD Performance

CNSY-45.2%

GTBP-67.3%

% from 52W High

CNSY-53.6%

GTBP-76.8%

% from 52W Low

CNSY30.0%

GTBP36.0%

Asset Turnover (TTM)

CNSY0.24x

GTBP0.08x

FCF Yield (TTM)

CNSY-267.6%

GTBP-4.9%

Earnings Yield (TTM)

CNSY-196.5%

GTBP-11.1%

Dividend Yield (TTM)

CNSYN/A

GTBPN/A

Rule of 40

CNSY-845.3

GTBP0.0

EV/GP/RG

CNSYN/A

GTBPN/A

Ticker research

View CNSY research View GTBP research

Metric	CNSY Plus Therapeutics Inc	GTBP GT Biopharma Inc
Market & Valuation
Market Cap	$13M	$296M
Enterprise Value	$11M	$291M
Price	$1.93	$6.68
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	174.71x
EV/Sales	2.60x	95.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	3.08x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	216.6%	216.5%
Profitability
Gross Margin (TTM)	0.0%	36.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	0.0%
Net Margin (TTM)	-620.7%	0.0%
FCF Margin (TTM)	-845.3%	N/A
Net Income (TTM)	$-26M	$-33M
FCF (TTM)	$-36M	$-14M
EPS (TTM)	-$3.78	-$21.10
ROE (TTM)	-39417.0%	-44308.0%
ROA (TTM)	-15136.0%	-31311.0%
ROIC (TTM)	-37414.0%	-44308.0%
Financial Health
Cash	$2M	$5M
Debt	$0	$0
Net Cash/Debt	$2M	$5M
Current Ratio (TTM)	1.37x	2.61x
Quick Ratio (TTM)	1.26x	2.51x
Debt/Equity (TTM)	0.19x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	0.81
52W Performance	-45.2%	-75.3%
YTD Performance	-45.2%	-67.3%
% from 52W High	-53.6%	-76.8%
% from 52W Low	30.0%	36.0%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.08x
FCF Yield (TTM)	-267.6%	-4.9%
Earnings Yield (TTM)	-196.5%	-11.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CNSY research	View GTBP research

Valuation

P/S Ratio

CNSY

3.16x

GTBP

174.71x

EV/FCF

GTBP

-20.19x

CNSY

-0.31x

Growth & revenue

Forward Revenue Growth

CNSY

216.6%

GTBP

216.5%

Profitability & performance

Gross Margin

GTBP

36.5%

CNSY

0.0%

ROE

CNSY

-39417.0%

GTBP

-44308.0%

FCF Yield %

GTBP

-4.9%

CNSY

-267.6%

52-Week Performance

CNSY

-45.2%

GTBP

-75.3%

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

GTBP

GT Biopharma Inc

Market Cap

CNSY$13M

GTBP$296M

Enterprise Value

CNSY$11M

GTBP$291M

Price

CNSY$1.93

GTBP$6.68

P/E Ratio

CNSYN/A

GTBPN/A

P/S Ratio

CNSY3.16x

GTBP174.71x

EV/Sales

CNSY2.60x

GTBP95.98x

EV/EBITDA

CNSY0.00x

GTBP0.00x

P/B Ratio

CNSY2.22x

GTBP3.08x

P/FCF Ratio

CNSYN/A

GTBPN/A

EV/FCF

CNSY-0.31x

GTBP-20.19x

PEG Ratio

CNSYN/A

GTBPN/A

Forward P/E (NTM)

CNSYN/A

GTBPN/A

Forward P/S (NTM)

CNSY1.12x

GTBPN/A

Revenue (TTM)

CNSY$4M

GTBP$0

Revenue Growth (YoY)

CNSYN/A

GTBPN/A

Forward Rev Growth

CNSY216.6%

GTBP216.5%

Gross Margin (TTM)

CNSY0.0%

GTBP36.5%

Operating Margin (TTM)

CNSY0.0%

GTBP0.0%

EBITDA Margin (TTM)

CNSY-612.0%

GTBP0.0%

Net Margin (TTM)

CNSY-620.7%

GTBP0.0%

FCF Margin (TTM)

CNSY-845.3%

GTBPN/A

Net Income (TTM)

CNSY$-26M

GTBP$-33M

FCF (TTM)

CNSY$-36M

GTBP$-14M

EPS (TTM)

CNSY-$3.78

GTBP-$21.10

ROE (TTM)

CNSY-39417.0%

GTBP-44308.0%

ROA (TTM)

CNSY-15136.0%

GTBP-31311.0%

ROIC (TTM)

CNSY-37414.0%

GTBP-44308.0%

Cash

CNSY$2M

GTBP$5M

Debt

CNSY$0

GTBP$0

Net Cash/Debt

CNSY$2M

GTBP$5M

Current Ratio (TTM)

CNSY1.37x

GTBP2.61x

Quick Ratio (TTM)

CNSY1.26x

GTBP2.51x

Debt/Equity (TTM)

CNSY0.19x

GTBP0.00x

Debt/Assets (TTM)

CNSY0.0%

GTBP0.0%

Interest Coverage (TTM)

CNSYN/A

GTBPN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

GTBP0.00x

Beta

CNSY2.21

GTBP0.81

52W Performance

CNSY-45.2%

GTBP-75.3%

YTD Performance

CNSY-45.2%

GTBP-67.3%

% from 52W High

CNSY-53.6%

GTBP-76.8%

% from 52W Low

CNSY30.0%

GTBP36.0%

Asset Turnover (TTM)

CNSY0.24x

GTBP0.08x

FCF Yield (TTM)

CNSY-267.6%

GTBP-4.9%

Earnings Yield (TTM)

CNSY-196.5%

GTBP-11.1%

Dividend Yield (TTM)

CNSYN/A

GTBPN/A

Rule of 40

CNSY-845.3

GTBP0.0

EV/GP/RG

CNSYN/A

GTBPN/A

Ticker research

View CNSY research View GTBP research

Metric	CNSY Plus Therapeutics Inc	GTBP GT Biopharma Inc
Market & Valuation
Market Cap	$13M	$296M
Enterprise Value	$11M	$291M
Price	$1.93	$6.68
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	174.71x
EV/Sales	2.60x	95.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	3.08x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	216.6%	216.5%
Profitability
Gross Margin (TTM)	0.0%	36.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	0.0%
Net Margin (TTM)	-620.7%	0.0%
FCF Margin (TTM)	-845.3%	N/A
Net Income (TTM)	$-26M	$-33M
FCF (TTM)	$-36M	$-14M
EPS (TTM)	-$3.78	-$21.10
ROE (TTM)	-39417.0%	-44308.0%
ROA (TTM)	-15136.0%	-31311.0%
ROIC (TTM)	-37414.0%	-44308.0%
Financial Health
Cash	$2M	$5M
Debt	$0	$0
Net Cash/Debt	$2M	$5M
Current Ratio (TTM)	1.37x	2.61x
Quick Ratio (TTM)	1.26x	2.51x
Debt/Equity (TTM)	0.19x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	0.81
52W Performance	-45.2%	-75.3%
YTD Performance	-45.2%	-67.3%
% from 52W High	-53.6%	-76.8%
% from 52W Low	30.0%	36.0%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.08x
FCF Yield (TTM)	-267.6%	-4.9%
Earnings Yield (TTM)	-196.5%	-11.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CNSY research	View GTBP research